Skip to main content

Main menu

  • Home
  • Current Issue
  • Past Issues
  • Videos
  • Submit an article
  • More
    • About JSF
    • Editorial Board
    • Published Ahead of Print (PAP)
  • IPR Logo
  • About Us
  • Journals
  • Publish
  • Advertise
  • Videos
  • Webinars
  • More
    • Awards
    • Article Licensing
    • Academic Use
  • Follow IIJ on LinkedIn
  • Follow IIJ on Twitter

User menu

  • Sample our Content
  • Request a demo
  • Log in

Search

  • ADVANCED SEARCH: Discover more content by journal, author or time frame
The Journal of Structured Finance
  • IPR Logo
  • About Us
  • Journals
  • Publish
  • Advertise
  • Videos
  • Webinars
  • More
    • Awards
    • Article Licensing
    • Academic Use
  • Sample our Content
  • Request a demo
  • Log in
The Journal of Structured Finance

The Journal of Structured Finance

ADVANCED SEARCH: Discover more content by journal, author or time frame

  • Home
  • Current Issue
  • Past Issues
  • Videos
  • Submit an article
  • More
    • About JSF
    • Editorial Board
    • Published Ahead of Print (PAP)
  • Follow IIJ on LinkedIn
  • Follow IIJ on Twitter

Pattern Risk of the Securitized Biopharmaceutical Mega-Fund

Carlos E. Ortiz, Charles A. Stone and Anne Zissu
The Journal of Structured Finance Summer 2020, 26 (2) 30-44; DOI: https://doi.org/10.3905/jsf.2020.1.103
Carlos E. Ortiz
is a professor in the Department of Mathematics and Computer Science at Arcadia University in Glenside, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles A. Stone
is a professor in the Koppelman School of Business at Brooklyn College of City University of New York in New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Zissu
is a professor at Citytech, City University of New York, and the Tandon School of Engineering of New York University in New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF (Subscribers Only)
Loading

Click to login and read the full article.

Don’t have access? Click here to request a demo 
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600

Abstract

Clinical-stage biopharmaceutical companies are constantly challenged to raise sufficient capital to advance the development of the drug projects in their pipelines. The risk of capital becoming too costly or unavailable when it is needed can constrain the development and commercialization of important medical advances. Securitization has been discussed as a way to increase the flow of capital to clinical-stage biopharmaceutical companies. For securitization to draw more capital into funding biopharmaceutical development, a technique for allocating the current and future cash flows associated with specific biopharmaceutical products must be developed. Fernandez et al. (2012), Fagnan et al. (2013), and Fagnan et al. (2014) have proposed a “mega-fund” scheme as the foundation for a clinical stage biopharmaceutical securitization structure. The securities issued to finance the “mega-fund” are called “Research Backed Obligations.” In this article, the authors modify their label by calling the securities structured biopharmaceutical-backed bonds (SBBBs). This model of the flows of cash through the SBBBs illustrates that it is not only the final number of projects that succeed that drives the value of the fund; also important are the timing of failure, the probability of failing in each phase of development, and the magnitude of success in each phase.

TOPICS: Legal and regulatory issues for structured finance, MBS and residential mortgage loans

Key Findings

  • • The pattern of drug development failure across the three phases of FDA clinical trials drives the portfolio value of the Biopharmaceutical Mega Fund.

  • • Incorporating licensing/royalty agreements between clinical stage biopharmaceutical companies that are developing the drugs that compose the biopharmaceutical mega-fund and commercial stage biopharmaceutical companies into the securitization program will alleviate adverse selection issues that could depress the value of the securities issued by the mega-fund.

  • • Pattern risk is the uncertain path of progress through the clinical stages of testing that the assets in the biopharmaceutical mega-fund follow. This risk can be managed by engineering the structured biopharmaceutical-backed bonds to account for variations in the patterns of clinical failure.

  • © 2020 Pageant Media Ltd
View Full Text

Don’t have access? Click here to request a demo

Alternatively, Call a member of the team to discuss membership options

US and Overseas: +1 646-931-9045

UK: 0207 139 1600

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

Explore our content to discover more relevant research

  • By topic
  • Across journals
  • From the experts
  • Monthly highlights
  • Special collections

In this issue

The Journal of Structured Finance: 26 (2)
The Journal of Structured Finance
Vol. 26, Issue 2
Summer 2020
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The Journal of Structured Finance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pattern Risk of the Securitized Biopharmaceutical Mega-Fund
(Your Name) has sent you a message from The Journal of Structured Finance
(Your Name) thought you would like to see the The Journal of Structured Finance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pattern Risk of the Securitized Biopharmaceutical Mega-Fund
Carlos E. Ortiz, Charles A. Stone, Anne Zissu
The Journal of Structured Finance Jul 2020, 26 (2) 30-44; DOI: 10.3905/jsf.2020.1.103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Save To My Folders
Share
Pattern Risk of the Securitized Biopharmaceutical Mega-Fund
Carlos E. Ortiz, Charles A. Stone, Anne Zissu
The Journal of Structured Finance Jul 2020, 26 (2) 30-44; DOI: 10.3905/jsf.2020.1.103
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Tweet Widget Facebook Like LinkedIn logo

Jump to section

  • Article
    • Abstract
    • BACKGROUND
    • DATA
    • THE MODEL
    • SIMULATIONS AND INTERPRETATION
    • CONCLUSION
    • ADDITIONAL READING
    • REFERENCES
  • Info & Metrics
  • PDF

Similar Articles

Cited By...

  • No citing articles found.
  • Google Scholar
LONDON
One London Wall, London, EC2Y 5EA
United Kingdom
+44 207 139 1600
 
NEW YORK
41 Madison Avenue, New York, NY 10010
USA
+1 646 931 9045
pm-research@pageantmedia.com
 

Stay Connected

  • Follow IIJ on LinkedIn
  • Follow IIJ on Twitter

MORE FROM PMR

  • Home
  • Awards
  • Investment Guides
  • Videos
  • About PMR

INFORMATION FOR

  • Academics
  • Agents
  • Authors
  • Content Usage Terms

GET INVOLVED

  • Advertise
  • Publish
  • Article Licensing
  • Contact Us
  • Subscribe Now
  • Log In
  • Update your profile
  • Give us your feedback

© 2022 Pageant Media Ltd | All Rights Reserved | ISSN: 1551-9783 | E-ISSN: 2374-1325

  • Site Map
  • Terms & Conditions
  • Cookies
  • Privacy Policy